| CAS NO: | 1215493-56-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 339.43 |
|---|---|
| Formula | C20H25N3O2 |
| CAS No. | 1215493-56-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 68 mg/mL (200.3 mM) |
| Water: <1 mg/mL | |
| Ethanol: 10 mg/mL (29.6 mM) | |
| SMILES | O=C(NCCCCCC(NC1=CC=CC=C1N)=O)C2=CC=C(C)C=C2 |
| Synonyms | RGFP 109; RGFP-109; RGFP109; RG2833; RG 2833; RG-2833 Chemical Name: N-(6-(2-Aminophenylamino)-6-oxohexyl)-4-methylbenzamide SMILES Code: O=C(NCCCCCC(NC1=CC=CC=C1N)=O)C2=CC=C(C)C=C2 |
| In Vitro | In vitro activity: RGFP109 dose-dependently upregulates frataxin mRNA and protein levels in cultures of unstimulated peripheral blood mononuclear cells (PBMC) obtained from FRDA patients. Kinase Assay: Aconitase activities are determined by homogenization of mouse brain tissues on ice at 10% w/v in CellLytic MT Mammalian Tissue Lysis/Extraction buffer, followed by centrifugation at 800×g for 10 min at 4°C. Tissue lysates (50 μL) are then added to 200 μL of substrate mix (50 mM Tris/HCl pH 7.4, 0.4 mM NADP, 5 mM Na citrate, 0.6 mM MgCl2, 0.1% (v/v) Triton X-100 and 1U isocitrate dehydrogenase) and the reactions are incubated at 37°C for 15 min, followed by spectrophotometric absorbance measurements every minute for 15 min at 340 nm 37°C to determine the reaction slope. Aconitase activities of mouse brain tissues are then normalized to citrate synthase activities, which are determined using a citrate synthase assay kit. Cell Assay: The Ki values of RG2833 for HDAC1 and HDAC3 are 5.4 nM and 7.8 nM, respectively. RG2833 is highly active in the whole tested concentration range from 1 to 10 μM. Continuous incubation with RG2833 slows the increase in frataxin protein, and when the compound is removed, frataxin protein levels rapidly increased in the cells from patient P13. RG2833 produces significant increases in brain aconitase enzyme activity, together with reduction of neuronal pathology of the dorsal root ganglia (DRG). |
|---|---|
| In Vivo | RG2833 (150 mg/kg) corrects frataxin deficiency and increases histone acetylation in the brain and heart of KIKI mice without acute toxicity signs. RGFP109 ameliorates the disease phenotype of a Friedreich ataxia mouse model. RGFP109 (30 mg/kg p.o.) also alleviates established l-DOPA-induced dyskinesia. |
| Animal model | Mice are housed in conventional open cages with Litaspen Premium 8/20 bedding, paper wool nesting and standard fun tunnel environmental enrichment, with 13 h light, 11 h dark, 20-23°C and 45-60% humidity. The mice are given a diet of SDS RM3 Expanded food pellets and standard drinking water. Mice are given subcutaneous injections of 150 mg/kg RG2833 three times per week for 4.5 months, or 50 mg/kg 136 or 100 mg/kg RG2833 five times per week for 5 months, followed by culling for tissue collection 24 h after the final injection. |
| Formulation & Dosage | Formulated in a vehicle solution of 20% glycerol, 20% PEG400, 20% propylene glycol, 5 mM Na acetate pH 5.2.; s.c. administration. |
| References | PLoS One. 2010 Jan 21;5(1):e8825; Neurobiol Dis. 2011 Jun;42(3):496-505; Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. |
m.cnreagent.com